Diflucan® Partnership Program
About the Program
Via
the Diflucan®
Partnership Program, Pfizer‘s
antifungal medicine Diflucan® (fluconazole) is made
available free of charge for the treatment of cryptococcal
meningitis and esophageal candidiasis, two opportunistic
infections associated with HIV/AIDS, to governments and
nongovernmental organizations in developing countries.
Countries with HIV/AIDS prevalence greater than 1 percent
will be given priority.
Diflucan® for donation is available in the following dosage
forms: 200 mg tablets (pink in color),
200 mg intravenous vials and 50 mg/5 ml powder for oral
suspension for pediatric use.
The Diflucan® Partnership Program Web site also provides
information for health professionals on the diagnosis
and treatment of cryptococcal meningitis and esophageal candidiasis. Click
here for more
information.
About the Partners
The Diflucan® Partnership Program
partners include:
-
IMA World
Health, a nonprofit organization that
provides essential products and services for emergency,
health and development programs, receives the initial
donation of
Diflucan® from Pfizer. IMA World Health reviews and approves
applications and provides the medicine to the successful
applicant organizations.
-
Pfizer Inc, a
worldwide pharmaceutical and health care company, manufactures
Diflucan®
and
donates it to IMA World Health.
-
Axios, a leader in implementing public
health programs, processes the applications, maintains databases and
monitors re-ordering for the applicant
organizations.
|
To
Apply for the Program
Governments and nongovernmental
organizations interested in applying
to receive Diflucan® via the
Diflucan® Partnership Program
should click
here
to access the necessary
documentation. |
 |
|
|
Working Together for a Healthier World™ |
